Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPTOP: Ranibizumab vs Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
jRCT1090220028Completed
- Sponsor
- Hyogo Macular Disease Study Group
- Start
- Jun 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of ranibizumab in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Hyogo Macular Disease Study Group. Primary endpoint: Visual acuity improvement at 12 months. Started Jun 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on jRCT1090220028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220028.